(NVS) Novartis - Ratings and Ratios

Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: US66987V1098

Cardiovascular, Oncology, Immunology, Neurology, Hematology

Stock: Pharmaceuticals
Age 34.2y
MCap 274,675m
Avg Vol 1.37M (192M USD)
Beta 0.222
Volatility 18.61%

EPS (Earnings per Share)

EPS (Earnings per Share) of NVS over the last years for every Quarter: "2020-12": 1.34, "2021-03": 1.52, "2021-06": 1.66, "2021-09": 1.71, "2021-12": 1.4, "2022-03": 1.46, "2022-06": 1.56, "2022-09": 1.58, "2022-12": 1.52, "2023-03": 1.71, "2023-06": 1.83, "2023-09": 1.74, "2023-12": 1.53, "2024-03": 1.8, "2024-06": 1.97, "2024-09": 2.06, "2024-12": 1.98, "2025-03": 2.28, "2025-06": 2.42, "2025-09": 2.25,
EPS CAGR: 13.49%
EPS Trend: 92.9%
Last SUE: -0.57
Qual. Beats: 0

Revenue

Revenue of NVS over the last years for every Quarter: 2020-12: 13030, 2021-03: 12694, 2021-06: 13294, 2021-09: 13367, 2021-12: 13522, 2022-03: 12814, 2022-06: 13085, 2022-09: 10783, 2022-12: 13087, 2023-03: 11047, 2023-06: 11745, 2023-09: 12092, 2023-12: 11776, 2024-03: 12120, 2024-06: 12872, 2024-09: 13172, 2024-12: 13558, 2025-03: 13620, 2025-06: 14836, 2025-09: 14358,
Rev. CAGR: 1.61%
Rev. Trend: 48.6%
Last SUE: 1.00
Qual. Beats: 2

Dividends

Dividend Yield 3.68%
Yield on Cost 5y 5.25%
Yield CAGR 5y 4.28%
Payout Consistency 96.5%
Payout Ratio 44.7%
Risk via 5d forecast
Volatility 18.6%
Value at Risk 5%th 29.8%
Relative Tail Risk -2.77%
Reward TTM
Sharpe Ratio 1.85
Alpha 48.76
CAGR/Max DD 1.27
Character TTM
Hurst Exponent 0.547
Beta 0.222
Beta Downside 0.215
Drawdowns 3y
Max DD 19.95%
Mean DD 4.61%
Median DD 3.83%

Description: NVS Novartis December 01, 2025

Novartis AG (NYSE:NVS) is a Swiss-based, globally integrated pharmaceutical company that discovers, develops, manufactures, and markets a broad portfolio of prescription medicines across therapeutic areas such as cardiovascular-renal-metabolic, immunology, neuroscience, oncology, and hematology.

Key marketed products include Entresto for HFrEF, Cosentyx for psoriasis and related inflammatory diseases, Kisqali (CDK4/6 inhibitor) for breast cancer, the Tafinlar + Mekinist combo for melanoma, Jakavi for myelofibrosis, and Leqvio (inclisiran) – a PCSK9-targeting LDL-cholesterol-lowering therapy co-developed with Alnylam.

From a financial-performance perspective, Novartis generated ≈ $53 billion in total revenue in 2023, with oncology contributing roughly 30 % of sales and a 2024-2026 R&D budget projected at $9-10 billion to sustain pipeline growth. The company’s earnings per share (EPS) has been trending upward, posting a 12 % YoY increase in Q3 2024, while its dividend yield remains above 3 %.

Sector-level drivers that materially affect Novartis include aging demographics driving demand for chronic-disease therapies, ongoing regulatory pressure on drug pricing in the U.S. and Europe, and the accelerating shift toward biologics and gene-therapy platforms – areas where Novartis has invested heavily (e.g., Zolgensma and upcoming CAR-T candidates).

For a deeper quantitative view of Novartis’ valuation metrics, see the ValueRay analysis.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income: 14.39b TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA 3.45 > 1.0
NWC/Revenue: -6.74% < 20% (prev 6.27%; Δ -13.02% < -1%)
CFO/TA 0.20 > 3% & CFO 21.07b > Net Income 14.39b
Net Debt (22.47b) to EBITDA (22.94b): 0.98 < 3
Current Ratio: 0.88 > 1.5 & < 3
Outstanding Shares: last quarter (1.94b) vs 12m ago -4.29% < -2%
Gross Margin: 76.21% > 18% (prev 0.75%; Δ 7546 % > 0.5%)
Asset Turnover: 53.48% > 50% (prev 48.24%; Δ 5.24% > 0%)
Interest Coverage Ratio: 15.68 > 6 (EBITDA TTM 22.94b / Interest Expense TTM 1.12b)

Altman Z'' 2.95

A: -0.04 (Total Current Assets 28.20b - Total Current Liabilities 32.00b) / Total Assets 107.29b
B: 0.41 (Retained Earnings 43.51b / Total Assets 107.29b)
C: 0.17 (EBIT TTM 17.53b / Avg Total Assets 105.41b)
D: 0.71 (Book Value of Equity 44.37b / Total Liabilities 62.54b)
Altman-Z'' Score: 2.95 = A

Beneish M -3.00

DSRI: 0.98 (Receivables 8.98b/8.15b, Revenue 56.37b/49.94b)
GMI: 0.98 (GM 76.21% / 74.92%)
AQI: 1.06 (AQ_t 0.63 / AQ_t-1 0.59)
SGI: 1.13 (Revenue 56.37b / 49.94b)
TATA: -0.06 (NI 14.39b - CFO 21.07b) / TA 107.29b)
Beneish M-Score: -3.00 = A

ValueRay F-Score (Strict, 0-100) 91.71

1. Piotroski: 9.0pt
2. FCF Yield: 5.74%
3. FCF Margin: 30.26%
4. Debt/Equity: 0.72
5. Debt/Ebitda: 0.98
6. ROIC - WACC: 16.65%
7. RoE: 34.12%
8. Revenue Trend: 48.64%
9. EPS Trend: 92.90%

What is the price of NVS shares?

As of January 25, 2026, the stock is trading at USD 147.14 with a total of 1,647,855 shares traded.
Over the past week, the price has changed by +1.94%, over one month by +5.76%, over three months by +11.77% and over the past year by +52.39%.

Is NVS a buy, sell or hold?

Novartis has received a consensus analysts rating of 2.85. Therefor, it is recommend to hold NVS.
  • Strong Buy: 0
  • Buy: 2
  • Hold: 9
  • Sell: 0
  • Strong Sell: 2

What are the forecasts/targets for the NVS price?

Issuer Target Up/Down from current
Wallstreet Target Price 134.9 -8.3%
Analysts Target Price 134.9 -8.3%
ValueRay Target Price 193.4 31.4%

NVS Fundamental Data Overview January 24, 2026

P/E Trailing = 19.5828
P/E Forward = 15.5763
P/S = 4.8725
P/B = 6.1961
P/EG = 1.1618
Revenue TTM = 56.37b USD
EBIT TTM = 17.53b USD
EBITDA TTM = 22.94b USD
Long Term Debt = 22.60b USD (from longTermDebt, last quarter)
Short Term Debt = 7.78b USD (from shortTermDebt, last quarter)
Debt = 32.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.47b USD (from netDebt column, last quarter)
Enterprise Value = 297.14b USD (274.68b + Debt 32.02b - CCE 9.56b)
Interest Coverage Ratio = 15.68 (Ebit TTM 17.53b / Interest Expense TTM 1.12b)
EV/FCF = 17.42x (Enterprise Value 297.14b / FCF TTM 17.06b)
FCF Yield = 5.74% (FCF TTM 17.06b / Enterprise Value 297.14b)
FCF Margin = 30.26% (FCF TTM 17.06b / Revenue TTM 56.37b)
Net Margin = 25.53% (Net Income TTM 14.39b / Revenue TTM 56.37b)
Gross Margin = 76.21% ((Revenue TTM 56.37b - Cost of Revenue TTM 13.41b) / Revenue TTM)
Gross Margin QoQ = 75.35% (prev 77.61%)
Tobins Q-Ratio = 2.77 (Enterprise Value 297.14b / Total Assets 107.29b)
Interest Expense / Debt = 0.88% (Interest Expense 281.0m / Debt 32.02b)
Taxrate = 6.34% (266.0m / 4.20b)
NOPAT = 16.42b (EBIT 17.53b * (1 - 6.34%))
Current Ratio = 0.88 (Total Current Assets 28.20b / Total Current Liabilities 32.00b)
Debt / Equity = 0.72 (Debt 32.02b / totalStockholderEquity, last quarter 44.33b)
Debt / EBITDA = 0.98 (Net Debt 22.47b / EBITDA 22.94b)
Debt / FCF = 1.32 (Net Debt 22.47b / FCF TTM 17.06b)
Total Stockholder Equity = 42.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.65% (Net Income 14.39b / Total Assets 107.29b)
RoE = 34.12% (Net Income TTM 14.39b / Total Stockholder Equity 42.18b)
RoCE = 27.07% (EBIT 17.53b / Capital Employed (Equity 42.18b + L.T.Debt 22.60b))
RoIC = 22.77% (NOPAT 16.42b / Invested Capital 72.14b)
WACC = 6.11% (E(274.68b)/V(306.70b) * Re(6.73%) + D(32.02b)/V(306.70b) * Rd(0.88%) * (1-Tc(0.06)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 86.59% ; FCFF base≈15.39b ; Y1≈17.29b ; Y5≈23.10b
Fair Price DCF = 319.2 (EV 634.95b - Net Debt 22.47b = Equity 612.49b / Shares 1.92b; r=6.11% [WACC]; 5y FCF grow 14.32% → 2.90% )
EPS Correlation: 92.90 | EPS CAGR: 13.49% | SUE: -0.57 | # QB: 0
Revenue Correlation: 48.64 | Revenue CAGR: 1.61% | SUE: 1.00 | # QB: 2
EPS next Year (2026-12-31): EPS=9.21 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+3.2% | Growth Revenue=+2.6%

Additional Sources for NVS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle